Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)
Phase III Clinical Trial
A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)